1
|
Siromoni B, Vedire Y, Rana N, Groman A, Mukherjee S. 87P Socio-demographic disparities in esophageal cancer: A SEER analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
2
|
Deng L, Groman A, Jiang C, Perimbeti S, Gabriel E, Kukar M, Mukherjee S. SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Torka P, Groman A, Wong J, Baysal B, Nichols J, Kader A, Mavis C, Jani Sait S, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez‐Ilizaliturri F. A PHASE 1 STUDY OF CARFILZOMIB WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (C‐RICE) IN TRANSPLANT‐ELIGIBLE RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.83_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- P. Torka
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - A. Groman
- Roswell Park Comprehensive Cancer Center Biostatistics Buffalo USA
| | - J. Wong
- Roswell Park Comprehensive Cancer Center Pathology Buffalo USA
| | - B. Baysal
- Roswell Park Comprehensive Cancer Center Pathology Buffalo USA
| | - J. Nichols
- Roswell Park Comprehensive Cancer Center Clinical Research Services Buffalo USA
| | - A. Kader
- Roswell Park Comprehensive Cancer Center Clinical Research Services Buffalo USA
| | - C. Mavis
- Roswell Park Comprehensive Cancer Center Immunology Buffalo USA
| | - S. Jani Sait
- Roswell Park Comprehensive Cancer Center Cytogenetics Buffalo USA
| | - A. Block
- Roswell Park Comprehensive Cancer Center Cytogenetics Buffalo USA
| | | | - A. Mohr
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - I. Lund
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - K. McWhite
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - J. Kostrewa
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - J. DeMarco
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - M. Johnson
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - A. Darrall
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - R.‐N. Thomas
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - S. Sundaram
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - P. Ghione
- Roswell Park Comprehensive Cancer Center Medicine Buffalo USA
| | - A. Hutson
- Roswell Park Comprehensive Cancer Center Biostatistics Buffalo USA
| | | |
Collapse
|
4
|
Das GM, Kulkarni S, Oturkar C, Edge SB, Wilton JH, Wang J, Swetzig WM, Adjei AA, Bies R, Hutson AD, Morrison CD, Kaipparettu BA, Groman A, Kumar S, Capuccino H. Abstract P5-04-04: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Das GM, Kulkarni S, Oturkar C, Edge SB, Wilton JH, Wang J, Swetzig WM, Adjei AA, Bies R, Hutson AD, Morrison CD, Kaipparettu BA, Groman A, Kumar S, Capuccino H. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-04.
Collapse
Affiliation(s)
- GM Das
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - S Kulkarni
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - C Oturkar
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - SB Edge
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - JH Wilton
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - J Wang
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - WM Swetzig
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - AA Adjei
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - R Bies
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - AD Hutson
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - CD Morrison
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - BA Kaipparettu
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - A Groman
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - S Kumar
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| | - H Capuccino
- Roswell Park Comprehensive Cancer Center, Buffalo, NY; Northwestern University, Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Baylor College of Medicine, Houston, TX
| |
Collapse
|
5
|
Hennon M, Kumar A, Devisetty H, D'Amico T, Demmy T, Groman A, Yendamuri S. MA23.09 Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Chen H, Dy G, Groman A, Farrell E, Miller A, Bushunow P, Adjei A. MA 01.06 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Chemotherapy-Resistant Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.446] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Singh A, Suescun JAG, Stephans K, Bogart J, Lili T, Malhotra H, Videtic G, Groman A. A Phase 2 Randomized Study of 2 Stereotactic Body Radiation Therapy Regimens for Medically Inoperable Patients With Node-Negative, Peripheral Non–Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.01.040] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
8
|
Ait-Oudhia S, Mager DE, Pokuri V, Tomaszewski G, Groman A, Zagst P, Fetterly G, Iyer R. Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT Pharmacometrics Syst Pharmacol 2016; 5:297-304. [PMID: 27300260 PMCID: PMC5131886 DOI: 10.1002/psp4.12084] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Accepted: 04/18/2016] [Indexed: 12/31/2022]
Abstract
Hepatocellular carcinoma (HCC) is third in cancer-related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a selective tyrosine kinase inhibitor of the angiogenic biomarker: soluble vascular endothelial growth factor receptor-2 (sVEGFR2 ). Sunitinib failed its primary overall survival endpoint in patients with advanced HCC in a phase III trial compared to sorafenib. In the present study, pharmacokinetic-pharmacodynamic modeling was used to link drug-exposure to tumor-growth-inhibition (TGI) and time-to-tumor progression (TTP) through sVEGFR2 dynamics. The results suggest that 1) active drug concentration (i.e., sunitinib and its metabolite) inhibits the release of sVEGFR2 and that such inhibition is associated with TGI, and 2) daily sVEGFR2 exposure is likely a reliable predictor for the TTP in HCC patients. Moreover, the model quantitatively links the dynamics of an angiogenesis biomarker to TTP and accurately predicts observed literature-reported results of placebo treatment.
Collapse
Affiliation(s)
- S Ait-Oudhia
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA
| | - D E Mager
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA
| | - V Pokuri
- Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - G Tomaszewski
- Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - A Groman
- Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - P Zagst
- Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | - G Fetterly
- Clinical Pharmacology and Regulatory Affairs, Buffalo, New York, USA
| | - R Iyer
- Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
| |
Collapse
|
9
|
Platek A, Jayaprakash V, Platek M, Gupta V, Cohan D, Hicks W, Winslow T, Groman A, Dibaj S, Arshad H, Kuriakose M, Warren G, Singh A. Subsite Variation in Oropharyngeal Squamous Cell Carcinomas in the Era of Human Papillomavirus: Tonsillar Fossa Has Improved Survival Compared to Base of Tongue. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.12.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Platek A, Jakaprakash V, Platek M, Gupta V, Cohan D, Hicks W, Winslow T, Groman A, Dibaj S, Arshad H, Kuriakose M, Warren G, Singh A. The Effect of Smoking and Human Papillomavirus Status on Survival in Oropharyngeal Squamous Cell Carcinoma Patients Undergoing Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.12.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Liu C, Miliotto A, Daudi S, Groman A, Lele S, Odunsi K. Expression and serum immunoreactivity identify cancer/testis genes 55 and 57 as immunotherapy targets in ovarian cancer. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Akers SN, Riebandt G, Miller A, Groman A, Odunsi K, Lele S. Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. EUR J GYNAECOL ONCOL 2013; 34:113-9. [PMID: 23781579 PMCID: PMC5100901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
OBJECTIVE To determine response rates (RR), progression-free survival (PFS), overall survival (OS), and toxicity in patients treated with cytotoxic chemotherapy, in combination with bevacizumab compared to cytotoxic chemotherapy alone, in the setting of recurrent ovarian cancer. MATERIALS AND METHODS After obtaining Institutional Review Board approval, two cohorts of patients with recurrent ovarian cancer were identified: 1) patients that received cytotoxic chemotherapy with bevacizumab from January 2006 to June 2009; 2) patients that received cytotoxic chemotherapy alone. RR were measured using RECIST criteria or by CA-125 levels using modified Rustin criteria. RR, OS, and PFS were determined using Kaplan-Meier survival analysis. RESULTS Thirty-two patients that received bevacizumab in combination with cytotoxic chemotherapy and 32 patients that received cytotoxic chemotherapy alone were identified. The control patients were matched for age, platinum response, histology, surgical outcome, grade, and number of previous chemotherapy regimens. There were no differences between the two cohorts in the rates of venous thromboembolism (VTE) (p = 0.39), bleeding (p = 0.15) or bowel obstruction (p = 0.40). The rate of hypertension in the bevacizumab cohort was greater than in the comparison cohort (p < 0.005). There were no differences in response rates PR/CR vs SD/PD (p = 0.46), OS (p = 0.79) or PFS (p = 0.43). CONCLUSIONS With increased toxicity, increased cost of therapy and no improvement in PFS or OS, the role of bevacizumab in patients with recurrent ovarian cancer warrants further investigation.
Collapse
Affiliation(s)
- S N Akers
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
| | | | | | | | | | | |
Collapse
|
13
|
Akers SN, Groman A, Odunsi K, Lele S, Frederick PJ. Adjuvant treatment for uterine leiomyosarcoma. EUR J GYNAECOL ONCOL 2013; 34:409-414. [PMID: 24475573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The aims of this study were to evaluate outcomes in women diagnosed with uterine leiomyosarcoma (LMS). A retrospective chart review was conducted. Fifty-eight women with LMS were identified. Of the evaluable 52 patients (six patients were excluded), 73% had Stage I/II disease, and 27% had Stage III/IV disease. Sixty-three percent of patients received chemotherapy (97% doxorubicin-based therapy), eight percent received radiation alone, and 29% received no therapy. For patients with Stage I/II disease, no improvement in OS was demonstrated when adjuvant therapy was administered. There was a significant difference in OS (p = 0.0005) for patients with advanced Stage (III/IV) disease that received adjuvant chemotherapy. OS of the entire group, when adjusted for stage, failed to reveal a significant survival advantage for those receiving chemotherapy-based (p = 0.22). The present findings suggest further research into the role of chemotherapy in early stage disease is needed to better refine optimal treatment.
Collapse
Affiliation(s)
- S N Akers
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA.
| | - A Groman
- Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - K Odunsi
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA
| | - S Lele
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA
| | - P J Frederick
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Elm Street, Buffalo, NY, USA
| |
Collapse
|
14
|
Kiran G, Kesterson JP, Ozerkan K, Kanis M, Groman A, Lele S. Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer. EUR J GYNAECOL ONCOL 2013; 34:522-526. [PMID: 24601043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
INTRODUCTION The optimum follow-up regimen after treatment for early-stage endometrial cancer with curative intent is unknown. The National Comprehensive Cancer Network recommends a physical exam and vaginal cytology every three to six months for two years then at six to 12 month intervals with annual chest X-rays (CXR). However, there is debate as to whether intensive follow-up results in an improvement in outcomes for those with recurrent endometrial cancer. OBJECTIVE To determine if intensive surveillance for recurrent cancer in women with early-stage endometrial cancer improves their outcomes. MATERIALS AND METHODS The Roswell Park Cancer Institute tumor registry was used to identify patients with Stage I and II endometrial cancer initially diagnosed and treated over an 18-year period, who subsequently recurred. Clinico-pathological variables were abstracted. Patients were divided into two groups, depending on their mode of diagnosis of recurrent cancer: 1) routine screening, or 2) symptomatic. The outcomes between the two groups were compared. RESULTS Fifty-two patients met inclusion criteria. Twenty-three patients were diagnosed via routine screening methods and 29 were symptomatic at presentation. Groups were equally represented with respect to age, stage, grade, adjuvant therapy, site of recurrence (local, distant), and time to recurrence (p > 0.05). Median survival time was 79 months for those diagnosed during routine screening and 80 months for symptomatic patients (p > 0.05). CONCLUSION Pap smear and CXR appear to be of limited utility as the present study has shown that women diagnosed as a result of intensive surveillance did not have a better outcome than those who presented when symptomatic.
Collapse
Affiliation(s)
- G Kiran
- Department of Obstetrics and Gynecology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
| | - J P Kesterson
- Division of Gynecologic Oncology, Penn State Hershey Medical Center Hershey, PA, USA
| | - K Ozerkan
- Division of Gynecologic Oncology, Uludag University, Bursa, Turkey
| | - M Kanis
- Mount Sinai Medical Center Department of Obstetrics and Gynecology, New York, NY, USA
| | - A Groman
- Department of Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA
| | - S Lele
- Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
| |
Collapse
|
15
|
Ademuyiwa FO, Groman A, Hong CC, Kumar S, Levine EG, Miller A, Ambrosone CB. Abstract P3-07-02: Time-trends in survival in young women with breast cancer in a SEER population-based study. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As mammography is not generally recommended to women under 40, it is reasonable to conclude that documented outcome improvements over time are attributable to treatment advances with screening playing a less important role. In order to determine the contribution of screening and treatment to improvements, we evaluated the odds of presenting with more advanced disease by time-period and examined the time-trends in outcome in a population-based cohort ≤50. We evaluated whether any outcomes differentials existed by ER status.
Methods: Patients in SEER diagnosed with breast cancer (BC) were divided into 4 by year of diagnosis (1990–1994, 1995–1999, 2000–2004, 2005–2008). Patients were also categorized into 2 age-groups: <40 and 40–50 years. Odds ratios for presenting with more advanced disease over the 4 time-periods were calculated for the 2 age-groups. Multivariate analysis was done to investigate the association of survival with time-period for the 2 age-groups by ER status.
Results: 110,629 patient records were included. Multivariate adjusted hazard ratio for mortality in women aged 40–50 with ER positive BC declined over time. Comparing all time periods to 1990–1994, the HR for mortality in 1995–1999 was 0.83 (0.77–0.89), 0.61 (0.57–0.65) in 2000–2004, and 0.35 (0.30–0.40) in 2005–2008 (p <.001). Those <40 years with ER positive BC also had mortality improvements over time (HR 0.86, 0.63, 0.26 for 1995–1999, 2000–2004, and 2005–2008 respectively). On the contrary, no mortality improvements were seen in women with ER negative disease. Trends in progressively worsening mortality over time were observed in this cohort.
A 1.3-fold increase in the odds of presenting with stage I BC was seen in women 40–50 years comparing the 3 latter time periods with 1990–1994. Similarly, in the same age group, there was a 2.12-fold likelihood of presenting with a tumor ≤1cm in 2005–2008 versus 1990–1994. In women <40 years at diagnosis, the probability of presenting with stage I disease was lower in the 3 latter time periods than in 1990–1994; and a 2.84-fold higher probability of presenting with stage III/IV disease was seen in 2005–2008 compared with 1990–1994.
Conclusions: Patients who are ER positive and between 40–50 years have had time-trend changes with improvements in breast cancer outcome and smaller tumors likely attributable to both screening and hormonal therapies. Patients who are <40 years and/or ER negative have not had improvements in breast cancer outcome.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-07-02.
Collapse
Affiliation(s)
| | | | | | - S Kumar
- Roswell Park Cancer Institute
| | | | | | | |
Collapse
|
16
|
Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. 6517 POSTER Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71828-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
17
|
Fakih M, Groman A, McMahon J, Romano K, Wisniewski M, Wilding G, Fetterly G, Muindi J. 6104 POSTER A Phase II Randomized Study of Two Doses of Vorinostat in Combination With 5-FU/LV in Patients With Refractory Colorectal Cancer (CRC). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71749-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
18
|
Kesterson J, Kiran G, Ozerkan K, Kanis M, Groman A, Lele S. Evaluation of the outcome benefit conferred by intensive surveillance strategies in women with early-stage endometrial cancer. Gynecol Oncol 2011. [DOI: 10.1016/j.ygyno.2010.12.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Ngamphaiboon N, Edge SB, Groman A, Wilding GE, Ademuyiwa F, Levine EG, Watroba N, O'Connor TL. Abstract P5-13-08: Factors Affecting Delivery of Planned Chemotherapy for Breast Cancer in Older Women. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-13-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent studies suggest that older women derive the same benefits from adjuvant systemic chemotherapy (AST) as younger women. In older women, the ability to successfully complete chemotherapy may be complicated by other health conditions and performance status. This study examines the frequency of inability to complete planned AST and factors associated with difficulty administering AST in older women.
Methods: We performed a retrospective analysis of breast cancer patients (age≥65) who received adjuvant/neoadjuvant chemotherapy at Roswell Park Cancer Institute from 9/1997 to 1/2010. Endpoints considered collectively as “difficulty “ in delivering AST were delay in treatment, hospitalization, dose reduction and discontinuation of AST. Factors defined a priori that could affect these outcomes were creatinine clearance (CCr), obesity (BMI ≥30), cardiac disease, hypertension, psychiatric disorders, diabetes, cerebrovascular disease, previous malignancy, COPD/asthma, Charlson comorbidity index, and use of anthracycline-based chemotherapy. The Pearson chi-squared test was used to identify the significant categorical factors associated with each of the five binary responses indicating difficulty administering AST. Logistic regression was used to obtain crude and adjusted odds ratios to further examine the relationships. Kaplan-Meier methods were used to estimate survival distributions, progression free and overall survival. The log-rank test was used for comparison between women experiencing difficulty with treatment and those with no difficulty with treatment. A 0.05 nominal significance level was used in all testing. Statistical analysis and plots were completed using SAS, version 9.2, statistical software (SAS Institute Inc., Cary, NC).
Results: 193 women age 65 and over received AST (median age of 70 years - range 65-86). Median follow up was 40.9 months. 73% received anthracycline-based AST. Factors associated with difficulty, delay, dose reduction, hospitalization, or failure to complete planned AST are shown in the Table. Women who completed planned AST had better OS than those who did not complete AST (p=0.01). Women who completed therapy with difficulty had no difference in outcome compared to those without difficulty [DFS (p=0.07) and OS (p=0.18)].
Conclusions: Age, cardiac disease, diabetes, hypertension, CCr, obesity, CCI, and sum of comorbidity significantly impact the ability to deliver and complete AST in older women with BC. Completing planned chemotherapy is associated with improved survival.
Figures available in online version.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-13-08.
Collapse
Affiliation(s)
| | - SB Edge
- Roswell Park Cancer Institute, Buffalo, NY
| | - A Groman
- Roswell Park Cancer Institute, Buffalo, NY
| | - GE Wilding
- Roswell Park Cancer Institute, Buffalo, NY
| | | | - EG Levine
- Roswell Park Cancer Institute, Buffalo, NY
| | - N Watroba
- Roswell Park Cancer Institute, Buffalo, NY
| | | |
Collapse
|
20
|
Rivera L, Khoury T, Tian L, Groman AE, Watroba NL, Murekeyisoni C, Sossey-Alaoui K, Kulkarni SA. Abstract P4-09-16: WAVE3 Over-Expression Is Associated with Adverse Tumor Characteristics and Mortality in Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-09-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: WAVE3 regulates actin polymerization and subsequent cell migration leading to enhanced metastatic potential. Based on pilot data that suggested WAVE3 expression was associated with high histologic grade and absence of estrogen receptor (ER) expression we hypothesized that WAVE3 expression would correlate with ER status and tumor grade in a matched group of breast cancer (BC) patients. WAVE3 expression was alsoanalyzed in relation to adverse tumor characteristics, distant recurrence (DR) and BC specific mortality. Methods: Our institutional BC database was reviewed for patients who presented with, invasive BC from 1999-2009. Matching by stage and treatment was achieved for 61 patients with Scarff-Bloom-Richardson (SBR) grade 1 and ER+ tumors (SBR1/ER+) to 61 patients with SBR grade 3 and ER-tumors (SBR3/ER-). Cytosolic WAVE3 tumor expression was determined by immunohistochemistry. The product of stain intensity (0-3) and percentage of cells staining (0-100) was used to derive a WAVE3 score (0-300). The log rank test was utilized to compare BC specific mortality or distant recurrence free survival at various WAVE3 scores. A score of ≥212 was found to have the strongest association with poor outcome. The association between WAVE3 score and clinicopatholigic features, DR and BC specific mortality was assessed. Results: Increased frequency of Her2-neu (+) status, DR and BC specific mortality was noted in the SBR3/ER-group but WAVE3 score was no different between the two groups(Table1). In all 122 patients median WAVE3 score increased with tumor size (0.234, p=0.009), (+) lymph node status 200 vs. (-), 145, p =0.03, and stage (I, 160 vs. II,180 vs III, 240, p=0.012). There was no association between WAVE3 score and Her2-neu status(+200 vs. -180, p=0.51). In the SBR1/ER+ group only (+) lymph node status remained associated with WAVE3 score(+) 200 vs. (-) 130 (p=0.02). In the SBR3/ER-group only lymph node status lost association with WAVE3 score (+)180 vs.(-)170, (p=0.50). DR and BC specific survival could only be assessed in the SBR3/ER-group. Median WAVE3 score was elevated with DR (240 vs. none, 160, p=0.03) and BC specific mortality (270 vs. none 170, p=0.004). A WAVE3 score ≥212 was associated with distant recurrence and BC specific mortality on Kaplan Meier analysis (p=0.01) and P<0.001). On multivariate analysis a WAVE3 score ≥212 was associated with an increased risk for BC specific mortality (p=0.009). The association of DR and WAVE3 score ≥212 approached significance (p=0.068).
Table 1
Conclusion: WAVE3 expression is not associated with tumor grade, and ER or Her2 neu status. WAVE3 is associated with tumor size, stage, DR and BC specific mortality in the high risk SBR3/ER-group. A WAVE3 score of ≥212 is associated with distant recurrence and breast cancer specific mortality on univariate analysis and BC specific mortality on uni-and multivariate analysis. WAVE3 expression may contribute to adverse outcome in high risk breast cancer patients.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-16.
Collapse
Affiliation(s)
- L Rivera
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - T Khoury
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - L Tian
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - AE Groman
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - NL Watroba
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - C Murekeyisoni
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - K Sossey-Alaoui
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| | - SA. Kulkarni
- Roswell Park Cancer Institute, Buffalo, NY; Cleveland Clinic Lerner Research Institute, OH
| |
Collapse
|
21
|
Hopkins S, Groman A, Saito N. Breslow Depth is a Risk Factor for Brain Metastases in Patients with Malignant Melanoma. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.694] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Mccall WV, Perlis ML, Tu X, Groman AE, Krystal A, Walsh JK. A comparison of placebo and no-treatment during a hypnotic clinical trial. Int J Clin Pharmacol Ther 2005; 43:355-9. [PMID: 16119510 DOI: 10.5414/cpp43355] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE Sleep parameters commonly improve during placebo treatment in insomnia clinical trials. We examined whether the improvement seen with placebo was related to taking pills or other non-specific factors. METHOD 95 insomniacs took either a placebo pill (pill+) or no pill (pill-) on nights of their choosing over 12 weeks. RESULTS Pills were consumed on about half of the nights. Consistent improvement was seen with reduced reported sleep latency, wakefulness after sleep onset, number of awakenings, and total sleep time over the 12 weeks for both the pill+ and pill condition. A difference between pill+ and pill- was detected only for total sleep time, and this difference favored pill+. CONCLUSIONS This study suggests that improvement seen during placebo treatment is more related to non-specific factors of participating in clinical trial than to pill taking behavior.
Collapse
Affiliation(s)
- W V Mccall
- Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1071, USA.
| | | | | | | | | | | |
Collapse
|
23
|
Andela VB, Siddiqui F, Groman A, Rosier RN. An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma. J Clin Pathol 2005; 58:328-30. [PMID: 15735172 PMCID: PMC1770605 DOI: 10.1136/jcp.2004.017640] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Dominant negative inhibition of nuclear factor kappa B (NF kappa B) signalling activity in a human osteosarcoma cell line (Saos2) results in malignant reversion and the induction of the osteoblast differentiating transcription factor, Runx2/Cbfa1. This observation suggests that there is an inverse relation between a transcription factor associated with malignant progression and chemoresistance (NF kappa B) and an osteoblast differentiating transcription factor (Runx2/Cbfa1). AIMS To assess and correlate Runx2/Cbfa1 and NF kappa B (p65) immunoreactivity in human osteosarcoma. METHODS Runx2/Cbfa1 and NFkappaB (p65) immunoreactivity was assessed on 11 paraffin wax embedded archival specimens of human primary osteosarcoma by standard immunohistochemical methods and scored on a scale of 0-3. A Pearson correlation analysis between Runx2/Cbfa1 and NF kappa B (p65) scores was established. RESULTS Runx2/Cbfa1 was expressed constitutively in all pathology specimens of human osteosarcoma. Of note, a chondroblastic osteosarcoma showed the highest Runx2/Cbfa1 immunoreactivity. A Pearson correlation did not support an inverse correlation between Runx2/Cbfa1 and NF kappa B (p65) scores (r = 0.57) in human osteosarcoma. CONCLUSION Runx2/Cbfa1 immunoreactivity does not inversely correlate with NF kappa B immunoreactivity, and thus cannot serve as an indirect measure of NF kappa B activity or an independent predictive or prognostic indicator.
Collapse
Affiliation(s)
- V B Andela
- The James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue Box 665, Rochester, NY 14642, USA.
| | | | | | | |
Collapse
|